Abstract
This study was conducted to evaluate the efficacy and safety of Rituximab, Gemcitabine, Cisplatin, and Dexamethasone (R-GDP) in relapsed or refractory aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL). Treatments consisted of rituximab 375 mg/m2, i.v. on day 1; gemcitabine 1,000 mg/m2, i.v. on days 1 and 8, dexamethasone 40 mg i.v. on days 1–4, and cisplatin 25 mg/m2 i.v. on days 1–3, every 21 days. The primary end-points were the overall survival (OS) and progression-free survival (PFS). Secondary endpoints included response rate (ORR; CR) and toxicities. Eligible patients could then proceed to high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) or receive up to six treatment cycles. From January 2005 to December 2010, 50 successive patients at Tianjin cancer hospital lymphoma department were enrolled in this study. All patients were recurrent or refractory aggressive B-cell NHL, including diffuse large B-cell lymphoma (n = 30) and follicular lymphoma grade 3b (n = 20). The median follow-up time was 42 months (range, 12–70). After two cycles, the overall response rate was 72.0 %, with a CR/CRu rate of 56 %. The 2-year OS and PFS of all patients were 70.0 and 48.0 %, respectively. Grade III–IV neutropenia and thrombocytopenia occurred in 34 and 40 % of patients, respectively. Twenty-one patients (42 %) proceeded to ASCT. Higher International Prognostic Index and refractory disease were independently associated with worse survival and progression-free survival. R-GDP chemotherapy in patients with refractory or relapsed aggressive B-Cell NHL was effective as a salvage therapy and helpful for HDC/ASCT.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Niitsu N. Current treatment strategy of diffuse large B-cell lymphomas. Int J Hematol. 2010;92(2):231–7.
Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fuju A, Wilson WH. Role of doxorubicin-containing regimen in relapsed and resistant lymphomas. an 8-year follow-up study of EPOCH. J Clin Oncol. 2000;21:3633–42.
Jermann M, Jost LM, Taverna C, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol. 2004;15(3):511–6.
Fossa A, Santoro A, Hiddemann W, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3786–92.
Bergman AM, Ruiz van Haparen V, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 1996;2:521–30.
Chau I, Harries M, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin’s and non-Hodgkin’s lymphoma. Br J Haematol. 2003;120:970–7.
Kim K-H, Joo Y-D, Sohn C-H, et al. Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin’s lymphoma. Korean J Intern Med. 2009;24(1):37–42.
Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008.
Vellenga E, van Putten WL, van ‘t Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20 + NHL: a prospective randomized HOVON trial. Blood. 2008;111:537–43.
Shrestha S, Johnson C, Jain S, et al. ESHAP ± rituximab as salvage therapy for relapsed lymphoma prior to stem cell transplant: single institution experience. Blood 2004;104: (abstract 4601).
Julie L, David S, Isabelle M, et al. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10(4):262–9.
Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol. 1997;24:(2 Suppl 7):S7-2–S7-7.
Agustín A, Natividad N, Judith HG, et al. Gemcitabine and cisplatin in refractory malignant lymphoma. Oncology. 2004;66:197–200.
Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–23.
El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007;18:1363–8.
Girouard C, Dufresne J, Imrie K, et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin’s lymphoma prior to autologous bone marrow transplantation. Ann Oncol. 1997;8:675–80.
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Hou, Y., Wang, Hq. & Ba, Y. Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma. Med Oncol 29, 2409–2416 (2012). https://doi.org/10.1007/s12032-012-0211-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-012-0211-2